Loading
CSO-20 / Overweight and Obesity / CSO-30 · Interventional Study
ClinicalTrials.gov · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registry record for an active, ongoing interventional study examining intermittent cottonseed oil consumption at two doses versus control on lipid and metabolic markers over 8 weeks. No results are posted; the study is still recruiting. The design and rationale are grounded in prior work by the investigator, but efficacy and safety remain unassessed.
Interventional, Randomized, Parallel, Double masking, Prevention purpose. Dyslipidemia, Overweight and Obesity, Nutrition, Healthy; age from 25 Years; to 75 Years; accepts healthy volunteers. Intervention: CSO-30; CSO-20. Compared with: Control — Placebo Comparator. n = 75. 1 site: United States.
This is a registry record for an active, ongoing interventional study examining intermittent cottonseed oil consumption at two doses versus control on lipid and metabolic markers over 8 weeks. No results are posted; the study is still recruiting. The design and rationale are grounded in prior work by the investigator, but efficacy and safety remain unassessed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Results from this study will inform whether intermittent (three times weekly) cottonseed oil consumption produces similar lipid and metabolic benefits to daily dosing, as suggested by the investigator's prior work. Clinical utility depends on efficacy results, which are not yet available.
This is a registry record for an ongoing interventional study with no reported results; recruitment is active and outcomes have not yet been measured or posted.
As stated by the source record.
Quoted from the source exactly as published.
Results from this study will inform whether intermittent (three times weekly) cottonseed oil consumption produces similar lipid and metabolic benefits to daily dosing, as suggested by the investigator's prior work. Clinical utility depends on efficacy results, which are not yet available.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07246408). This is a study registration, not published results. Lead sponsor: University of Georgia. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 75 participants (ESTIMATED). Conditions: Dyslipidemia, Overweight and Obesity, Nutrition, Healthy. Interventions: OTHER: CSO-30; OTHER: CSO-20; OTHER: Control. Primary outcome measures: Change in fasting serum lipoprotein and cholesterol concentrations , baseline, 8 weeks; Change in fasting and postprandial plasma triglyceride concentrations , baseline, 8 weeks; Change in fasting and postprandial plasma non-esterified fatty acid (NEFA) concentrations , baseline, 8 weeks. Brief summary: Cardiovascular disease risk factors, including higher BMIs and poor cholesterol profiles, are on the rise and contribute to the United States' growing disease burden. Cottonseed oil (CSO) is found readily in the food supply, and the investigator's previous studies have demonstrated that incorporating CSO into the diet is sufficient to improve fasting and postprandial blood lipids and other markers of chronic disease risk in both healthy and at-risk populations. This study aims to examine the impact of intermittent CSO consumption at different doses (consumed three times per week (3x/wk)) on changes in fasting and postprandial lipid metabolism/blood lipids and markers of chronic disease risk. The specific aims are: \*Examine the impact of intermittent CSO consumption (3x/week) at two different doses on fasting and postprandial lipids. \*Examine the impact of intermittent CSO consumption (3x/week) at two different doses on other markers of chronic disease risk. Participants will be asked to: \*Consume provided meal replacement shakes and snacks 3 times per week for 56 days. \*Attend three bi-weekly (every other week) short visits for fasting blood draws, body measurements, and collection of the next two weeks' study materials. \*Attend two longer (5.5h) testing visits, which include eating a standardized breakfast meal and having blood drawn periodically before and after breakfast. Researchers will compare CSO-30, CSO-20, and Control groups (receiving no oil) to see if intermittent CSO consumption imparts the same health benefits as previously shown with daily doses of CSO.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.